Anticancer Activity of Fisetin via KEAP1, DNMT1, and mTOR Axis Against Colon Cancer: An Integrated In Silico, In Vitro, and In Vivo Approach
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Satyam Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Hajipur, India. Hauptthemen laut MEDLINE: Flavonols, TOR Serine-Threonine Kinases, Kelch-Like ECH-Associated Protein 1, Colonic Neoplasms. Die Arbeit nennt 71 Literaturangaben. Gefördert von: This work was supported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India..
Abstract (Originalsprache)
The proliferation of colon cancer is influenced by alterations in epigenetic, reactive oxygen species (ROS), and dysregulation of signaling pathways, especially via the involvement of DNMT1, mTOR, and KEAP1 axis. The current investigation examined the antiproliferative capabilities of fisetin (FisT) in a rat model and in colon cancer cell lines HCT116, CT‐26, and Caco‐2. Our findings show that FisT modulated the DNMT1, mTOR, KEAP1, and IL‐6 signaling pathways to enhance the antiproliferative effects against in vitro and in vivo preclinical model. In‐silico based anticancer potential of fisetin were revealed through SwissTargetPrediction, Cytoscape, STRING, Schrodinger, molecular dynamics simulations, KEGG, and network analysis. In‐vitro MTT assay, cell cycle analysis, ROS level, immunocytofluorescence, western blot analysis, and in vivo immunohistofluorescence, western blot analysis, ELISA‐based assays were performed to evaluate anticancer property of fisetin. Our findings revealed that FisT has a strong anticancer property by demethylating DNA, enhancing ROS, KEAP1 level. Simultaneously downregulated the DNMT1 & mTOR expression, and preventing angiogenesis, cell proliferation, invasion, and migration against in vitro & in vivo models. FisT enhances the anticancer response of tumor development and reduces the size of crypt foci. FisT has potential as a cytotoxic drug, improving and intensifying anticancer responses in colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Hajipur, India.
- Department of Pharmacology, Indian Institute of Technology-Banaras Hindu University, Varanasi, India.
ORCID-Profile: Satyam Sharma, Sairam Krishnamurthy, Sanjiv Singh
Förderung
- This work was supported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India.
Zitieren
APA
Sharma, S., Mudgal, R., Krishnamurthy, S., & Singh, S. (2025). Anticancer Activity of Fisetin via KEAP1, DNMT1, and mTOR Axis Against Colon Cancer: An Integrated In Silico, In Vitro, and In Vivo Approach. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70391
Vancouver
Sharma S, Mudgal R, Krishnamurthy S, Singh S. Anticancer Activity of Fisetin via KEAP1, DNMT1, and mTOR Axis Against Colon Cancer: An Integrated In Silico, In Vitro, and In Vivo Approach. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70391
BibTeX
@article{Sharma2025,
author = {Sharma, Satyam and Mudgal, Rajat and Krishnamurthy, Sairam and Singh, Sanjiv},
title = {Anticancer Activity of Fisetin via KEAP1, DNMT1, and mTOR Axis Against Colon Cancer: An Integrated In Silico, In Vitro, and In Vivo Approach},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70391}
}
EUVIMED